Shares of Immunovant Inc. (NASDAQ:IMVT) were up 30% in midmorning trading after the firm disclosed early but “compelling” data from a phase IIb study testing next-generation FcRn inhibitor IMVT-1402 ...
From connected diagnostic wearables to smart everyday products: Mouser Electronics has expanded its dedicated online resource ...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); ...
Serious infection risk in older adults with RA appears to be driven more by modifiable clinical factors rather than the age at which RA develops.
Investor's Business Daily on MSN
These two biotech stocks rocketed — and one just broke out
Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment.
Aboard Air Force One (AFP) | 15/05/2026 - 13:11:51 | Trump says Xi 'feels strongly' Iran can't have nuclear weapon ...
One fifth of pregnant women are not being screened in a timely manner for syphilis, according to a new study in Ontario.
My wife is suffering from a failed back surgery that was caused by a neurosurgeon. The operation was four years ago, and she ...
Labour is set to announce a new timeline on HS2 and efforts to save money after years of delays and spiralling costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results